| Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010 | 5369 | 2010 |
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ... Journal of Clinical Oncology 24 (16), 2505-2512, 2006 | 1308 | 2006 |
| Tumour heterogeneity in the clinic PL Bedard, AR Hansen, MJ Ratain, LL Siu Nature 501 (7467), 355-364, 2013 | 1300 | 2013 |
| Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ... Journal of Clinical Oncology 22 (8), 1382-1388, 2004 | 1161 | 2004 |
| UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity L Iyer, S Das, L Janisch, M Wen, J Ramirez, T Karrison, GF Fleming, ... The pharmacogenomics journal 2 (1), 43-47, 2002 | 843 | 2002 |
| Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite … L Iyer, CD King, PF Whitington, MD Green, SK Roy, TR Tephly, ... The Journal of clinical investigation 101 (4), 847-854, 1998 | 843 | 1998 |
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis T Eisen, T Ahmad, KT Flaherty, M Gore, S Kaye, R Marais, I Gibbens, ... British journal of cancer 95 (5), 581-586, 2006 | 795 | 2006 |
| Perceptions of cancer patients and their physicians involved in phase I trials. C Daugherty, MJ Ratain, E Grochowski, C Stocking, E Kodish, R Mick, ... Journal of Clinical Oncology 13 (5), 1062-1072, 1995 | 631 | 1995 |
| Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea E Gupta, TM Lestingi, R Mick, J Ramirez, EE Vokes, MJ Ratain Cancer research 54 (14), 3723-3725, 1994 | 624 | 1994 |
| Measuring financial toxicity as a clinically relevant patient‐reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST) JA De Souza, BJ Yap, K Wroblewski, V Blinder, FS Araújo, FJ Hlubocky, ... Cancer 123 (3), 476-484, 2017 | 621 | 2017 |
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ... Journal of Clinical Oncology 29 (19), 2660, 2011 | 618 | 2011 |
| Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, ... Journal of Clinical Oncology 36 (16), 1611, 2018 | 513 | 2018 |
| The development of a financial toxicity patient‐reported outcome in cancer: the COST measure JA De Souza, BJ Yap, FJ Hlubocky, K Wroblewski, MJ Ratain, D Cella, ... Cancer 120 (20), 3245-3253, 2014 | 494 | 2014 |
| Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism L Iyer, D Hall, S Das, MA Mortell, J Ramírez, S Kim, A Di Rienzo, ... Clinical Pharmacology & Therapeutics 65 (5), 576-582, 1999 | 440 | 1999 |
| Oral chemotherapy: rationale and future directions. MD DeMario, MJ Ratain Journal of clinical oncology 16 (7), 2557-2567, 1998 | 362 | 1998 |
| Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung MJ Ratain, LS Kaminer, JD Bitran, RA Larson, MM Le Beau, C Skosey, ... | 318 | 1987 |
| Pharmacogenomics: challenges and opportunities DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ... Annals of internal medicine 145 (10), 749-757, 2006 | 306 | 2006 |
| The pharmacogenetics research network: from SNP discovery to clinical drug response KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ... Clinical Pharmacology & Therapeutics 81 (3), 328-345, 2007 | 304 | 2007 |
| Pharmacokinetic variability of anticancer agents SD Undevia, G Gomez-Abuin, MJ Ratain Nature Reviews Cancer 5 (6), 447-458, 2005 | 299 | 2005 |
| Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents JE Dancey, KK Dobbin, S Groshen, JM Jessup, AH Hruszkewycz, ... Clinical cancer research 16 (6), 1745-1755, 2010 | 295 | 2010 |
